Ra Capital Management, L.P. Adaptimmune Therapeutics PLC Transaction History

Ra Capital Management, L.P.

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 May 17, 2021	SELL	$4.9 - $6.83 $12.2 Million - $17.1 Million	-2,499,025 Closed	0 $0
Q4 2020 Feb 16, 2021	SELL	$4.0 - $9.2 $35.3 Million - $81.2 Million	-8,830,556 Reduced 77.94%	2,499,025 $13.5 Million
Q3 2020 Nov 16, 2020	SELL	$7.66 - $10.78 $13.2 Million - $18.6 Million	-1,722,883 Reduced 13.2%	11,329,581 $90.4 Million
Q2 2020 Aug 14, 2020	BUY	$2.58 - $12.1 $1.32 Million - $6.18 Million	510,576 Added 4.07%	13,052,464 $131 Million
Q1 2020 May 15, 2020	BUY	$1.2 - $4.52 $15.1 Million - $56.7 Million	12,541,888 New	12,541,888 $34.1 Million

145M

60.8K

5.8K

Ticker ADAP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 163,370,000
Market Cap $98M
Description
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4...

Get notified when there are updates to the investment portfolio of Ra Capital Management, L.P., based on Form 13F filings with the SEC.

Stay updated on Ra Capital Management, L.P. with notifications on news.